Performance of Novartis’s Innovative Medicines Segment in 3Q16



Innovative Medicines segment

Novartis’s (NVS) Innovative Medicines segment, formerly the Pharmaceutical segment, consists of products for therapeutic areas such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The overall contribution of the segment was ~67.0% at ~$8.2 billion for 3Q16.

Innovative Medicines includes two business units: Novartis Pharmaceuticals and Novartis Oncology.

Article continues below advertisement

Performance of key innovative medicines products

Novartis’s growth products, including Gilenya, Tasigna, Galvus, Mekinist + Tafinlar, Promacta/Revolade, Jakavi, Entresto, and Cosentyx, reported a 21.0% rise in revenues at constant currencies to $3.8 billion for 3Q16. That’s nearly 46.0% of total segment sales for the quarter.

Gilenya is an oral therapy for multiple sclerosis. Due to increased demand, revenues rose 15.0% at constant exchange rates to $790.0 million in 3Q16 compared to 3Q15. The drug had double-digit growth in most markets. Gilenya competes with Biogen’s (BIIB) Tecfidera and Sanofi’s (SNY) Aubagio.

Tasigna, a drug for the treatment of chronic myeloid leukemia, reported an 8.0% rise in revenues at constant exchange rates to $441.0 million in 3Q16. The rise followed double-digit growth in global markets, offset by a 1.0% fall in US markets. Tasigna competes with Pfizer’s (PFE) Bosulif.

Tafinlar + Mekinist is used in the treatment of BRAF V600+ metastatic melanoma. The combination is approved in more than 60 countries for the treatment of unresectable melanoma and in 35 countries for the treatment of metastatic melanoma. The combination reported a rise of 29.0% at constant exchange rates to $172.0 million in 3Q16.

To avoid the risk of investing in one company, you can consider ETFs such as the First Trust Value Line Dividend ETF (FVD), which holds ~0.50% of its total assets in Novartis.


More From Market Realist